Group V sPLA 2 Hydrolysis of Low-Density Lipoprotein Results in Spontaneous Particle Aggregation and Promotes Macrophage Foam Cell Formation
- 1 April 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 24 (4) , 762-767
- https://doi.org/10.1161/01.atv.0000122363.02961.c1
Abstract
Objectives— Secretory phospholipase A2 (sPLA2) enzymes hydrolyze the sn-2 fatty acyl ester bond of phospholipids to produce a free fatty acid and a lysophospholid. Group V sPLA2 is expressed in cultured macrophage cells and has high affinity for phosphatidyl choline-containing substrates. The present study assesses the presence of group V sPLA2 in human and mouse atherosclerotic lesions and its activity toward low-density lipoprotein (LDL) particles. Methods and Results— Group V sPLA2 was detected in human and mouse atherosclerotic lesions by immunohistochemical staining. Electron microscopic analysis showed that mouse group V sPLA2-modified LDL is significantly smaller (mean diameter±SEM=25.3±0.25 nm) than native LDL (mean diameter±SEM=27.7±0.29 nm). Hydrolysis by group V sPLA2 induced spontaneous particle aggregation; the extent of aggregation was directly proportional to the degree of LDL hydrolysis. Group V sPLA2 modification of LDL led to enhanced lipid accumulation in cultured mouse peritoneal macrophage cells. Conclusions— Group V sPLA2 may play an important role in promoting atherosclerotic lesion development by modifying LDL particles in the arterial wall, thereby enhancing particle aggregation, retention, and macrophage uptake.Keywords
This publication has 30 references indexed in Scilit:
- New phospholipase A2 isozymes with a potential role in atherosclerosisCurrent Opinion in Lipidology, 2003
- Secreted phospholipase A2enzymes as therapeutic targetsEmerging Therapeutic Targets, 2003
- Potent Modification of Low Density Lipoprotein by Group X Secretory Phospholipase A2 Is Linked to Macrophage Foam Cell FormationJournal of Biological Chemistry, 2002
- NONOXIDATIVE MODIFICATIONS OF LIPOPROTEINS IN ATHEROGENESISAnnual Review of Nutrition, 1999
- Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pHJournal of Biological Chemistry, 1998
- Binding of Human Phospholipase A2 Type II to ProteoglycansJournal of Biological Chemistry, 1996
- Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion systemAtherosclerosis, 1996
- Alterations in the physicochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label studyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996
- Secretory group II phospholipase A2 in human atherosclerotic plaquesAtherosclerosis, 1995
- Enhanced macrophage uptake of low density lipoprotein after self-aggregation.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988